CA3139411A1 - Novel peptide compound or pharmaceutically acceptable salt thereof - Google Patents

Novel peptide compound or pharmaceutically acceptable salt thereof Download PDF

Info

Publication number
CA3139411A1
CA3139411A1 CA3139411A CA3139411A CA3139411A1 CA 3139411 A1 CA3139411 A1 CA 3139411A1 CA 3139411 A CA3139411 A CA 3139411A CA 3139411 A CA3139411 A CA 3139411A CA 3139411 A1 CA3139411 A1 CA 3139411A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
peptide compound
novel peptide
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3139411A
Other languages
English (en)
French (fr)
Inventor
Yoo Seok Kim
Myoung Hwan Kim
Young In Kim
Taek Joo Lim
Hyeong Joon Lim
Jee Young Kim
Eun Young Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyebio Korea
Original Assignee
Eyebio Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyebio Korea filed Critical Eyebio Korea
Publication of CA3139411A1 publication Critical patent/CA3139411A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/54—Proteins
    • A23V2250/55—Peptide, protein hydrolysate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
CA3139411A 2019-05-21 2020-05-20 Novel peptide compound or pharmaceutically acceptable salt thereof Pending CA3139411A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2019-0059628 2019-05-21
KR20190059628 2019-05-21
PCT/KR2020/006594 WO2020235932A1 (ko) 2019-05-21 2020-05-20 신규한 펩타이드 화합물 또는 이의 약제학적으로 허용 가능한 염

Publications (1)

Publication Number Publication Date
CA3139411A1 true CA3139411A1 (en) 2020-11-26

Family

ID=73458705

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3139411A Pending CA3139411A1 (en) 2019-05-21 2020-05-20 Novel peptide compound or pharmaceutically acceptable salt thereof

Country Status (15)

Country Link
US (2) US12428446B2 (https=)
EP (2) EP3974441B1 (https=)
JP (1) JP7576048B2 (https=)
KR (2) KR20200134175A (https=)
CN (1) CN114269769B (https=)
AU (1) AU2020277930B2 (https=)
BR (1) BR112021023477A2 (https=)
CA (1) CA3139411A1 (https=)
ES (1) ES3012499T3 (https=)
MX (1) MX2021014051A (https=)
MY (1) MY205382A (https=)
PL (1) PL3974441T3 (https=)
SG (1) SG11202112276RA (https=)
WO (1) WO2020235932A1 (https=)
ZA (1) ZA202109175B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021023477A2 (pt) 2019-05-21 2022-02-15 Eyebio Korea Novo composto peptídico, composição farmacêutica para prevenir ou tratar inflamação, composição de alimento para prevenir ou amenizar a inflamação e composição de cosmético tendo um efeito anti inflamatório
KR102593936B1 (ko) * 2021-12-13 2023-10-27 주식회사 아이바이오코리아 신규한 펩타이드를 포함하는 황반변성의 치료용 조성물
EP4450079A4 (en) * 2021-12-13 2025-12-10 Eyebiokorea Inc COMPOSITION FOR THE TREATMENT OF MACULAR DEGENERATION COMPRISING A NEW PEPTIDE
KR20230089987A (ko) 2021-12-14 2023-06-21 주식회사 아이바이오코리아 펩타이드 약물을 포함하는 안구 투여용 약학 조성물
WO2023224454A1 (ko) 2022-05-20 2023-11-23 주식회사 엘지화학 양극 활물질 및 이의 제조방법
KR102587729B1 (ko) 2023-02-27 2023-10-12 주식회사 아이바이오코리아 펩타이드를 포함하는 당뇨망막병증의 치료용 조성물
KR102728422B1 (ko) * 2024-05-27 2024-11-11 주식회사 아이바이오코리아 염증성 질환의 치료 효과를 갖는 신규한 펩타이드 및 이의 용도

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084555A (en) 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
IT1241761B (it) * 1990-08-03 1994-02-01 Menarini Farma Ind Peptidi di sintesi antagonisti della neurochinina a, loro sali e relativi procedimenti di fabbricazione
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
WO2004074312A2 (en) * 2003-02-05 2004-09-02 University Of Ulster Tryptophyllin peptides and uses thereof
NZ577196A (en) 2005-01-20 2011-06-30 Biomarck Pharmaceuticals Ltd Mucin hypersecretion inhibitors based on the structure of MANS and methods of use
US8378070B2 (en) 2007-03-12 2013-02-19 Ramot At Tel-Aviv University Ltd. Peptides for the regulation of neurotransmitter sequestration and release
AU2008297541A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20090074672A1 (en) 2007-09-17 2009-03-19 Sri International Tumor Boundary Imaging
JP5299956B2 (ja) 2008-09-29 2013-09-25 国立大学法人東北大学 質量分析装置を用いた代謝酵素群の一斉タンパク質定量に用いるペプチド
WO2011060349A1 (en) 2009-11-13 2011-05-19 North Carolina State University Methods of modulating mesenchymal stem cells
CA2869599C (en) * 2012-04-13 2021-07-27 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (ii)
WO2013158230A1 (en) 2012-04-19 2013-10-24 The Regents Of The University Of California Compositions and methods for detecting unstable arteriosclerotic plaques
KR101438744B1 (ko) 2012-08-02 2014-09-15 전남대학교산학협력단 아디포넥틴을 유효성분으로 포함하는 안구건조증 또는 염증성 안구표면 질환의 예방 또는 치료용 조성물
KR101721059B1 (ko) 2014-12-26 2017-03-30 주식회사 아이바이오코리아 안구 표면 질환 예방 또는 치료용 약학조성물
KR101810163B1 (ko) 2016-04-08 2018-01-25 주식회사 아이바이오코리아 안구 표면질환 예방 또는 치료용 약학조성물
KR101798183B1 (ko) * 2016-04-08 2017-11-15 주식회사 아이바이오코리아 건성안 예방 또는 치료용 약학조성물
EP3539559B1 (en) 2016-04-08 2020-08-26 Eyebio Korea Collagen type ii alpha-1-based peptide for use in the treatment of macular degeneration
KR101795650B1 (ko) 2016-05-12 2017-11-09 인제대학교 산학협력단 아플리버셉트-콜라겐 타입 ii 펩타이드의 키메라 단백질을 유효성분으로 함유하는 혈관신생 억제용 조성물
KR101795653B1 (ko) 2016-05-19 2017-11-09 인제대학교 산학협력단 콜라겐 타입 ii 펩타이드-아플리버셉트의 키메라 단백질을 유효성분으로 함유하는 혈관신생 억제용 조성물
JP2019524673A (ja) * 2016-06-28 2019-09-05 バロリゼーション−ルシェルシュ，リミテッド パートナーシップ 新規な環状ペプチドおよびその使用
HUP1700012A2 (en) * 2017-01-06 2018-07-30 Evolveritas Kft Novel proteins and use thereof
EP3609519B1 (en) * 2017-04-11 2025-11-26 University of Maryland, Baltimore Compositions and methods for treating inflammation and cancer
RU2766160C2 (ru) * 2017-05-17 2022-02-08 Юю Фарма, Инк. Новый пептид и фармацевтический состав для лечения глазного заболевания, содержащий пептид в качестве активного фармацевтического ингредиента
CN107814840B (zh) * 2017-12-12 2020-04-10 浙江辉肽生命健康科技有限公司 一种生物活性多肽pkypvepf及其制备方法和应用
CN108727472A (zh) * 2018-06-07 2018-11-02 南方医科大学 带负电荷的细胞穿透肽及作为细胞内运送载体的用途
TWI865470B (zh) 2018-11-14 2024-12-11 南韓商柳柳製藥股份有限公司 治療眼睛疾病之肽及醫藥組合物
BR112021023477A2 (pt) 2019-05-21 2022-02-15 Eyebio Korea Novo composto peptídico, composição farmacêutica para prevenir ou tratar inflamação, composição de alimento para prevenir ou amenizar a inflamação e composição de cosmético tendo um efeito anti inflamatório

Also Published As

Publication number Publication date
JP7576048B2 (ja) 2024-10-30
EP4483959A3 (en) 2025-06-04
EP4483959A2 (en) 2025-01-01
SG11202112276RA (en) 2021-12-30
KR102523943B1 (ko) 2023-04-20
CN114269769B (zh) 2024-12-06
EP3974441A1 (en) 2022-03-30
PL3974441T3 (pl) 2025-04-07
EP3974441B1 (en) 2024-12-04
KR20200134175A (ko) 2020-12-01
EP3974441A4 (en) 2023-10-18
ES3012499T3 (en) 2025-04-09
ZA202109175B (en) 2024-04-24
WO2020235932A1 (ko) 2020-11-26
BR112021023477A2 (pt) 2022-02-15
US20240228538A1 (en) 2024-07-11
KR20220062252A (ko) 2022-05-16
US12428446B2 (en) 2025-09-30
JP2022533991A (ja) 2022-07-27
MX2021014051A (es) 2022-02-11
AU2020277930B2 (en) 2024-06-13
CN114269769A (zh) 2022-04-01
US20240352071A1 (en) 2024-10-24
MY205382A (en) 2024-10-18
AU2020277930A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
CA3139411A1 (en) Novel peptide compound or pharmaceutically acceptable salt thereof
ZA202206923B (en) New methylquinazolinone derivatives
EP4043478A4 (en) CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION
EP4335439A3 (en) Compounds
AU2018271990A1 (en) Covalent inhibitors of KRAS
EP4041278A4 (en) ACTIVE POLYPEPTIDE COMPOUND
ZA202007737B (en) Pentacyclic compound
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
EP4049680A4 (en) NEW SUBSTITUTED CONDENSED RING CONNECTION
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
EP3978511A4 (en) NOROVIRUS BINDING PEPTIDE
ZA202205158B (en) Polypeptide having mmp2-inhibitory effect
EP4223878A4 (en) SARS-COV-2 BINDING PEPTIDE
WO2020055360A3 (en) The parenteral composition comprising carfilzomib
EP3995506A4 (en) NOROVIRUS BINDING PEPTIDE
EP4649947A3 (en) Methods for treating against viruses
WO2021107514A3 (ko) 리피테그라스트의 제조방법
EP3930720A4 (en) COMPOUNDS USEFUL AS ADJUVANTS
HK40077506A (zh) Q-er肽
EP4001292A4 (en) SEPARATION PEPTIDE
EP3911372B8 (en) Compound targeting norepinephrine transporter
MY208423A (en) Composition of aminopyran derivative
WO2020043749A8 (en) New delivery system
EM87259640016S (bg) Туника
WO2019151967A3 (en) Water-dispersible tablet formulations comprising deferasirox

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230518

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240911

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250109

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250425

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250425

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250512

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250512

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251021

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260223

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260302

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260302

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260302

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20260305

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260330